Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
56 hedge funds and large institutions have $23.5M invested in Viracta Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 6 closing their positions.
114% more call options, than puts
Call options by funds: $186K | Put options by funds: $87K
0% more funds holding
Funds holding: 56 → 56 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
3% less capital invested
Capital invested by funds: $24.2M → $23.5M (-$662K)
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
+$791K |
| 2 |
Renaissance Technologies
New York
|
+$107K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$14.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.2K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.87M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$69.7K |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$40.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$31.8K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$17.9K |
VIRX Hedge Fund Activity: Q2 2016 in Review
56 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2016, worth a combined $23.5M — down 2.7% from $24.2M a quarter earlier.
Fund positioning in VIRX was balanced in Q2 2016: 6 funds opened new positions, 6 closed out, 9 added to existing stakes and 15 trimmed.
The largest buyer was First Eagle Investment Management, opening a new position worth an estimated $791K. The largest seller was Fidelity Investments, cutting an estimated $1.87M.
- 56 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $23.5M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2016, down 2.7% quarter-over-quarter.
- 6 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2016 and 6 closed out, a net change of 0 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2016 was First Eagle Investment Management, an estimated $791K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2016 was Fidelity Investments, an estimated $1.87M sold.
Based on aggregated 13F filings for Q2 2016.